Effectiveness of XBB.1.5 Monovalent COVID‐19 Vaccines During a Period of XBB.1.5 Dominance in EU/EEA Countries, October to November 2023: A VEBIS‐EHR Network Study
Influenza and Other Respiratory Viruses · 2024
DOI: 10.1111/irv.13292 ↗Kurz gefasst
Fachartikel in der Zeitschrift Influenza and Other Respiratory Viruses, 2024. Verfasst von Susana Monge und 21 weiteren Autor:innen. Beteiligte Einrichtung: Department of Communicable Diseases, National Centre of Epidemiology, Institute of Health Carlos III, Madrid, Spain. Hauptthemen laut MEDLINE: COVID-19, COVID-19 Vaccines, European Union, Hospitalization. Die Arbeit wurde bisher 31-mal zitiert (Crossref) und nennt 15 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: European Centre for Disease Prevention and Control, FCT - Fundação para a Ciência e Tecnologia, I.P..
Abstract (Originalsprache)
Using a common protocol across seven countries in the European Union/European Economic Area, we estimated XBB.1.5 monovalent vaccine effectiveness (VE) against COVID‐19 hospitalisation and death in booster‐eligible ≥ 65‐year‐olds, during October–November 2023. We linked electronic records to construct retrospective cohorts and used Cox models to estimate adjusted hazard ratios and derive VE. VE for COVID‐19 hospitalisation and death was, respectively, 67% (95%CI: 58–74) and 67% (95%CI: 42–81) in 65‐ to 79‐year‐olds and 66% (95%CI: 57–73) and 72% (95%CI: 51–85) in ≥ 80‐year‐olds. Results indicate that periodic vaccination of individuals ≥ 65 years has an ongoing benefit and support current vaccination strategies in the EU/EEA.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Communicable Diseases, National Centre of Epidemiology, Institute of Health Carlos III, Madrid, Spain.
- CIBER on Infectious Diseases, Madrid, Spain.
- Epiconcept, Paris, France.
- Vaccine Preventable Diseases and Immunisation, European Centre for Disease Prevention and Control (ECDC), Solna, Sweden.
- Sciensano, Elsene, Belgium.
- Department of Infectious Disease Epidemiology and Prevention, Statens Serum Institut, Copenhagen, Denmark.
ORCID-Profile: Jesús Castilla, Brechje de Gier, Esther Kissling
Förderung
- European Centre for Disease Prevention and Control
- FCT - Fundação para a Ciência e Tecnologia, I.P.
Zitieren
APA
Monge, S., Humphreys, J., Nicolay, N., Braeye, T., Van Evercooren, I., Holm Hansen, C., Emborg, H. D., Sacco, C., Mateo-Urdiales, A., Castilla, J., Martínez-Baz, I., de Gier, B., Hahné, S., Meijerink, H., Kristoffersen, A. B., Machado, A., Soares, P., Nardone, A., Bacci, S., …, & VEBIS‐EHR Working Group (2024). Effectiveness of XBB.1.5 Monovalent COVID‐19 Vaccines During a Period of XBB.1.5 Dominance in EU/EEA Countries, October to November 2023: A VEBIS‐EHR Network Study. Influenza and Other Respiratory Viruses. https://doi.org/10.1111/irv.13292
Vancouver
Monge S, Humphreys J, Nicolay N, Braeye T, Van Evercooren I, Holm Hansen C, et al. Effectiveness of XBB.1.5 Monovalent COVID‐19 Vaccines During a Period of XBB.1.5 Dominance in EU/EEA Countries, October to November 2023: A VEBIS‐EHR Network Study. Influenza and Other Respiratory Viruses. 2024. doi:10.1111/irv.13292
BibTeX
@article{Monge2024,
author = {Monge, Susana and Humphreys, James and Nicolay, Nathalie and Braeye, Toon and Van Evercooren, Izaak and Holm Hansen, Christian and Emborg, Hanne-Dorthe and Sacco, Chiara and Mateo-Urdiales, Alberto and Castilla, Jesús and Martínez-Baz, Iván and de Gier, Brechje and Hahné, Susan and Meijerink, Hinta and Kristoffersen, Anja Bråthen and Machado, Ausenda and Soares, Patricia and Nardone, Anthony and Bacci, Sabrina and Kissling, Esther and Nunes, Baltazar and VEBIS‐EHR Working Group, VEBIS‐EHR Working Group},
title = {Effectiveness of XBB.1.5 Monovalent COVID‐19 Vaccines During a Period of XBB.1.5 Dominance in EU/EEA Countries, October to November 2023: A VEBIS‐EHR Network Study},
journal = {Influenza and Other Respiratory Viruses},
year = {2024},
doi = {10.1111/irv.13292}
}
EUVIMED